Seven Eight Capital, LP Esperion Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$24.2 - $35.76 $458,372 - $677,330	-18,941 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$31.18 - $52.71 $590,580 - $998,380	18,941 New	18,941 $704,000
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $322,071 - $514,670	-8,707 Closed	0 $0
Q3 2018 Oct 18, 2018	SELL	$40.74 - $51.41 $554,064 - $699,176	-13,600 Reduced 60.97%	8,707 $386,000
Q2 2018 Aug 07, 2018	BUY	$36.2 - $76.4 $807,513 - $1.7 Million	22,307 New	22,307 $874,000
Q4 2017 Feb 12, 2018	SELL	$43.47 - $67.43 $1.02 Million - $1.58 Million	-23,398 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$43.8 - $52.77 $943,057 - $1.14 Million	21,531 Added 1153.24%	23,398 $1.17 Million
Q2 2017 Aug 10, 2017	BUY	N/A	1,867	1,867 $86,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.